Pregled bibliografske jedinice broj: 1175395
The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real- world Clinical Setting
The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real- world Clinical Setting // Clinical Psychopharmacology and Neuroscience, 20 (2022), 1; 118-125 doi:10.9758/cpn.2022.20.1.118 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1175395 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Impact of Long-acting Paliperidone in Reducing
Hospitalizations and Clinical Severity in Recent
Onset Schizophrenia: A Mirror-image Study in Real-
world Clinical Setting
Autori
Peitl, Vjekoslav ; Aukst Margetić, Branka ; Vidrih, Branka ; Karlović, Dalibor
Izvornik
Clinical Psychopharmacology and Neuroscience (1738-1088) 20
(2022), 1;
118-125
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
antipsychotic agents ; paliperidone palmitate ; pragmatic clinical trials ; psychotic disorders
Sažetak
Objective: Schizophrenia is a debilitating disease that disrupts the lives of many affected individuals and exerts a toll on the health system. Only few studies assessed once-monthly injectable formulation of paliperidone palmitate (PP-1M) and other long-acting antipsychotics in recent onset schizophrenia (ROS). To evaluate whether PP-1M is efficacious in reducing frequency and length of hospitalizations and psychosis symptom severity in patients with ROS. Methods: This mirror-image study included 112 patients, suffering from ROS admitted in a psychiatric ward and successively treated with PP- 1M for 1-year. Other psychotic disorders were excluded. We collected socio-demographic data of all subjects included, number and days of hospitalization, as well as Clinical Global Impression-Severity scale (CGI-S) and Clinician- Rated Dimensions of Psychosis Symptom Severity (CRDPSS) scores at the initiation and after 1-year of PP treatment. Results: After 1-year PP-1M treatment, mean scores of both CGI and CRDPSS significantly decreased (p < 0.001), as well as the mean number of hospitalizations (p = 0.002) and total hospitalization days (p < 0.001) in comparison with those of the previous year. Conclusion: Our results suggest that PP-1M can be considered as an important therapeutic option in patients with ROS. Its use led to a meaningful reduction in the patient’s use of hospital services, as well as a significant clinical improvement of psychotic symptoms in our sample.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Hrvatsko katoličko sveučilište, Zagreb
Profili:
Vjekoslav Peitl
(autor)
Dalibor Karlović
(autor)
Branka Vidrih
(autor)
Branka Aukst Margetić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus